Dr Mehrotra trained as a medical doctor at Guy’s, Kings and St Thomas’s Hospitals (GKT) Medical School, London, qualifying as a medical doctor (Bachelor of Medicine and Surgery) in 1995. He has subsequently trained further in central London teaching hospitals.
He completed his basic and specialist psychiatry training from the Kings College/Maudsley Hospital scheme in London. During this time he obtained specialist training in Cognitive Analytical Therapy.
He was awarded Membership of Royal College of Psychiatrist (MRCPsych) in 2000. Dr Mehrotra has been on the Specialist Register as a Consultant Psychiatrist for General Adult Psychiatry & Rehabilitation Psychiatry since 2003.
He was appointed as a Wellcome Trust Research Psychiatrist from 2000-2002, Section of Cognitive Psychopharmacology at the Institute of Psychiatry (Kings College), London leading to a number of publications in peer reviewed journals as well as developing expert skills in the use of psychotropic medicines.
He has been awarded higher postgraduate qualifications including recognition as an legal expert in psychiatry.
Dr Mehrotra provides Consultant input to inpatient wards and to community patients treating a broad range of conditions including personality disorder, depression, anxiety, post traumatic disorder (PTSD), dementia, bipolar disorder, schizophrenia and dual diagnosis.
Many of these patients have associated substance misuse and alcohol problems and experience socioeconomic deprivation. A substantial proportion of these patients are from ethnic minorities and do not speak English as their first language.
- Certificate in Good Clinical Practice (National Institute of Health Research)
- Bond Solon Civil Procedure Rules for Expert Witnesses Certificate
- Membership Expert Witness Institute (MEWI)
- Approved under Section 12 of the Mental Health Act by the Department of Health
- Membership of the Royal College of Psychiatrists (MRCPsych)
- General Medical Council – Full Registration
- Medical degree (MB BS) Guy’s, Kings and St Thomas’s Medical School, University of London
- 2013 ICE Project/ Finalist for the BMJ award 2013 ‘Transforming patient care through Technology’ category
- 2010 Trust Quality Award Excellence through Learning- Runner up ICE Project
- 2008 Trust Quality Award Innovation- Winner
- 2008 Trust Quality Award Valuing Difference in Recovery- Runner up
- 2007 Nomination for national award for Innovation, Health Service Journal
- 2007 Nomination for national award for Innovation, Care Services Improvement Partnership (CSIP)
- R Mehrotra and A Mukherjee (2013)
The characteristics of law breaking behaviour in First Episode Psychosis
Poster and Abstract at the European Congress of Psychiatry 2013
- S Otero and Ravi Mehrotra (2009)
Structural neuroimaging in first-episode psychosis, Technology Appraisal 136: Use of neuroimaging in early intervention service patients in Hounslow
Abstract submission at European Congress of Psychiatry 2011
- Anantha P. P. Anilkumar, Veena Kumari, Ravi Mehrotra, et al (2008)
An fMRI study of face encoding and recognition in first-episode schizophrenia
Acta Neuropsychiatrica June 2008 – Vol. 20 Issue 3 ,pages 129–138
- Veena Kumari, Anantha PP Anilkumar, Dominic H ffytche, Ravi Mehrotra et al (2008)
Neural Effects of Ziprasidone Monotherapy in First-Episode Schizophrenia: A Longitudinal Study using fMRI and a Procedural Learning Paradigm
Journal Clinical Schizophrenia & Related Psychoses. Volume 1, Number 4 / 317-327
- Halari R,Mehrotra R et al (2006)
Does self-perceived mood predict more variance in cognitive performance than clinician rated symptoms in schizophrenia?”
Schizophrenia Bulletin Oct 32(4) 751-758
- Postma P,Gray JA,Sharma T,Geyer M,Mehrotra R et al (2006).
A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia
Psychopharmacology (Berl). Feb;184(3-4):589-599
- Halari R,Mehrotra R et al (2006).
Cognitive impairment but preservation of sexual dimorphism in cognitive abilities in chronic schizophrenia.
Psychiatry Res. Jan 18
- Antonova E, Kumari V, Morris R, Halari R, Anilkumar A, Mehrotra R et al.(2005).
The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study.
Biol Psychiatry. Sep 15;58(6):457-67.
- Halari R, Hines M, Kumari V, Mehrotra R et al.(2005)
Sex differences and individual differences in cognitive performance and their relationship to endogenous gonadal hormones and gonadotropins.
Behav Neurosci. Feb;119(1):104-17.
- Young AM, Kumari V, Mehrotra R et al (2005).
Disruption of learned irrelevance in acute schizophrenia in a novel continuous within-subject paradigm suitable for fMRI
Behav Brain Res. Jan 30;156(2):277-88.
- Halari R, Wheeler M, Mehrotra R et al (2004).
The relationship of sex hormones and cortisol with cognitive functioning in schizophrenia.
J Psychopharmacol. Sep;18(3):366-74.
- Das M, Kumari V, Soni W, Ettinger U, Binneman B, Hughes C, Mehrotra R et al(2004).
Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia.
Schizophr Bull. 2004; 30(2): 241-53.
- Kumari V, Zachariah E, Galea A, Jones HC, Das M, Mehrotra R et al (2003).
Effects of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: a double-blind, placebo-controlled study.
J Psychopharmacol. Mar;17(1):89-95.
- Zachariah E, Kumari V, Galea A, Das M, Mehrotra R, et al.(2002).
Effects of oral procyclidine administration on cognitive functions in healthy subjects: implications for schizophrenia
J Clin Psychopharmacol. Apr;22(2):224-6.
- Kumari V, Zachariah E, Mehrotra R et al (2001).
Effects of procyclidine on prepulse inhibition of the acoustic startle response in healthy human volunteers.
Psychopharmacology Mar; 154 (3): 221-9.
- Mehrotra R et al (2000).
Neurological soft signs in schizophrenia: cognitive, clinical and structural correlates.
Schizophrenia Research, 41 (1), 262 (abstract).
- Soni W, Mehrotra R et al (2000).
Change in negative symptoms with risperidone predicts improved quality of life in schizophrenia.
Schizophrenia Research, 41 (1), 66 (abstract).